Clinical Trials for Mesothelioma Patients: Pemetrexed, Cisplatin, and Vitamin B12 Study outline
Read the outline for a clinical trial being conducted to study the effects of Pemetrexed, Cisplatin, and Vitamin B12 for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only. At this time, this study is only being conducted in Lille, France.
Outline:
This is a multicenter study. Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive vitamin B12 intramuscularly on day -7 and then every 9 weeks until chemotherapy is completed.
Blood samples are collected during the first and third courses of chemotherapy. Samples are analyzed by pharmacogenetic (MTHFR, TS, GSTpi, ERCC1, xPD), pharmacokinetic, and other pharmacological methods.
Disease Characteristics:
Inclusion criteria:
• Histologically confirmed pleural mesothelioma o Unresectable diseaseExclusion criteria:
• Clinically detected pleural effusion or ascites that cannot be controlled by drainage or other proceduresCourtesy of ClinicalTrials.gov.
Other helpful links:
Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney
Clinical study of Cisplatin and Pemetrexed on mesothelioma cancer